Item 4.01 Changes in Registrant's Certifying Accountant.
Based on information provided by Friedman LLP ("Friedman"), the independent
registered public accounting firm of Integrated BioPharma, Inc. (the "Company"),
effective September 1, 2022, Friedman combined with Marcum LLP ("Marcum"),
although continued to operate as an independent registered public accounting
firm with respect to the Company. On October 21, 2022, the Company dismissed
Friedman and engaged Marcum to serve as the independent registered public
accounting firm of the Company, which actions were ratified by the Audit
Committee of the Board of Directors of the Company. The services previously
provided by Friedman will now be provided by Marcum.
The audit reports of Friedman on the financial statements of the Company for the
years ended June 30, 2022 and 2021 and the subsequent interim period through
October 21, 2022 did not contain an adverse opinion or a disclaimer of opinion
and were not qualified or modified as to uncertainty, audit scope or accounting
principles.
During the Company's two most recent fiscal years ended June 30, 2022 and 2021
2021 and the subsequent interim period through October 21, 2022, there were no
(i) disagreements with Friedman on any matter of accounting principles or
practices, financial statement disclosure or auditing scope or procedures which,
if not resolved to Friedman's satisfaction, would have caused it to make
reference to the subject matter of the disagreement in connection with its
reports, or (ii) "reportable events" as defined in Item 304(a)(1)(v) of
Regulation S-K.
The Company provided Friedman with a copy of the foregoing disclosures and
requested it to furnish the Company with a letter addressed to the Securities
and Exchange Commission stating whether it agrees with the statements made by
the Company in the foregoing disclosures. A copy of the letter has been filed as
Exhibit 16.1 to this report.
During the Company's two most recent fiscal years ended June 30, 2022 and 2021
and the subsequent interim period through October 21, 2022, neither the Company
nor anyone on its behalf has consulted with Marcum regarding either (i) the
application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered on
the Company's financial statements, and neither a written report nor oral advice
was provided to the Company that Marcum concluded was an important factor
considered by the Company in reaching a decision as to any accounting, auditing
or financial reporting issue, or (ii) any matter that was either the subject of
a "disagreement" or a "reportable event," as such terms are defined in
Regulation S-K Item 304(a)(1)(iv) and (v), respectively.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
16.1 Letter from Friedman LLP to the Securities and Exchange Commission,
dated October 24, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
-1-
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses